First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Durvalumab
Related studies linked through entity extraction aliases.
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.
- Status
- COMPLETED
- Phase
- PHASE2
Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients
- Status
- WITHDRAWN
- Phase
- PHASE2
Efficacy and Safety of CRT, Durvalumab and Surgery for SST
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Durvalumab and Lenvatinib in Participants With Advanced and Recurrent Endometrial Carcinoma
- Status
- UNKNOWN
- Phase
- NA
Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC
- Status
- TERMINATED
- Phase
- PHASE2
Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC
- Status
- COMPLETED
- Phase
- PHASE4
Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
- Status
- RECRUITING
- Phase
- PHASE2
ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy
- Status
- TERMINATED
- Phase
- PHASE2
Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.
- Status
- UNKNOWN
- Phase
- N/A
Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects
- Status
- COMPLETED
- Phase
- PHASE2